The objective of our study was to explore the possibility of the antifungal efficacy of various micafungin dosage regimens against Candida spp in HIV positive patients with EC. According to pharmacokinetic/pharmacodynamics parameters of micafungin in HIV positive patients and MICs distribution of micafungin against Candida spp. in published studies, the dosage regimens of micafungin were 50, 100 and 150 mg QD iv. Monte Carlo Simulation analysed the probability of target attainment and cumulative fraction of response. The results showed that micafungin has good antifungal effect in treating HIV positive patients with EC when pathomycetes are Candida albicans, Candida glabrata or Candida tropicalis, in dosage at 100 mg QD and 150 mg QD.
References
[1]
Kyriakidis, I., Tragiannidis, A., Munchen, S., et al. (2017) Clinical Hepatotoxicity Associated with Antifungal Agents. Expert Opinion on Drug Safety, 16, 149-165.
[2]
Enoch, D.A., Yang, H.N., Aliyu, S.H., et al. (2017) The Changing Epidemiology of Invasive Fungal Infections. Methods in Molecular Biology, 1508, 17-65. https://doi.org/10.1007/978-1-4939-6515-1_2
[3]
Under, N., Stevenson, P. and Baraldi, E. (2012) Pharmacokinetics of Micafungin in HIV Positive Patients with Confirmed Esophageal Candidiasis. European Journal of Drug Metabolism and Pharmacokinetics, 37, 31-38. https://doi.org/10.1007/s13318-011-0063-8
[4]
Chen, S.C., Slavin, M.A. and Sorrell, T.C. (2011) Echinocandin Antifungal Drugs in Fungal Infections: A Comparison. Drugs, 71, 11-41. https://doi.org/10.2165/11585270-000000000-00000
[5]
Carver, P.L. (2004) Micafungin. The Annals of Pharmacotherapy, 38, 1707-1721. https://doi.org/10.1345/aph.1D301
[6]
Muilwijk, E.W., Lempers, V.J.C., Burger, D.M., et al. (2015) Impact of Special Patient Populations on the Pharmacokinetics of Echinocandins. Expert Review of Anti-Infective Therapy, 13, 799-815. https://doi.org/10.1586/14787210.2015.1028366
[7]
Wasmann, R.E., Muilwijk, E.W., Burger, D.M., et al. (2018) Clinical Pharmacokinetics and Pharmacodynamics of Micafungin. Clinical Pharmacokinetics, 57, 267-286. https://doi.org/10.1007/s40262-017-0578-5
[8]
Maesaki, S., Hossain, M.A., Miyazaki, Y., et al. (2000) Efficacy of FK463, a (1,3)-beta-D-glucan Synthase Inhibitor, in Disseminated Azole-Resistant Candida Albicans Infection in Mice. Antimicrobial Agents and Chemotherapy, 44, 1728-1730. https://doi.org/10.1128/AAC.44.6.1728-1730.2000
[9]
Messer, S.A., Diekema, D.J., Boyken, L., et al. (2006) Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp. Journal of Clinical Microbiology, 44, 324-326. https://doi.org/10.1128/JCM.44.2.324-326.2006
[10]
Pfaller, M.A., Boyken, L., Hollis, R.J., et al. (2008) In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance. Journal of Clinical Microbiology, 46, 150-156. https://doi.org/10.1128/JCM.01901-07
[11]
Warn, P.A., Sharp, A., Morrissey, G., et al. (2002) In Vivo Activity of Micafungin in a Persistently Neutropenic Murine Model of Disseminated Infection Caused by Candida tropicalis. Journal of Antimicrobial Chemotherapy, 50, 1071-1074. https://doi.org/10.1093/jac/dkf247
[12]
Wasmann, R.E., Smit, C., Heine, R., et al. (2019) Pharmacokinetics and Probability of Target Attainment for Micafungin in Normal-Weight and Morbidly Obese Adults. Journal of Antimicrobial Chemotherapy, 74, 978-985. https://doi.org/10.1093/jac/dky554
[13]
Boonstra, J.M., van der Elst, K.C., Veringa, A., et al. (2017) Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis. Antimicrobial Agents and Chemotherapy, 61, pii: e01398-17. https://doi.org/10.1128/AAC.01398-17
[14]
García-de-Lorenzo, A., Luque, S., Grau, S., et al. (2016) Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection. Antimicrobial Agents and Chemotherapy, 60, 5914-5921. https://doi.org/10.1128/AAC.00727-16
[15]
Xu, G.Q., Zhu, L.Q., Ge, T.Y., et al. (2016) Optimal Micafungin Dosage Regimens in Pediatric Patients with Invasive Candida Infection. Chinese Journal of New Drugs and Clinical Remedies, 35, 482-486.
[16]
Lepak, A.J. and Andes, D.R. (2015) Antifungal Pharmacokinetics and Pharmacodynamics. Cold Spring Harbor Perspectives in Medicine, 5, a019653. https://doi.org/10.1101/cshperspect.a019653
[17]
Wasmann, R.E., Muilwijk, E.W., Burger, D.M., et al. (2018) Clinical Pharmacokinetics and Pharmacodynamics of Micafungin. Clinical Pharmacokinetics, 57, 267-286. https://doi.org/10.1007/s40262-017-0578-5
[18]
Yang, Q.T., Wang, T.T., Xie, J., et al. (2016) Pharmacokinetic/Pharmacodynamic Adequacy of Echinocandins against Candida spp. in Intensive Care Unit Patients and General Patient Populations. International Journal of Antimicrobial Agents, 47, 397-402. https://doi.org/10.1016/j.ijantimicag.2016.02.004
